No. 2 TCU takes on No. 1 Texas and will make its first Elite Eight appearance thanks to star Hailey Van Lith. Here's how much ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

The cloud giant AI wars are heating up with Google announcing its Gemini 2.5 model and Amazon countering with the launch of ...

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

Mashable's shopping experts are still keeping track of the best deals available on Amazon during as the Big Spring Sale, even ...

ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

We recently published a list of Jim Cramer Looked At These 23 Stocks Recently. In this article, we are going to take a look ...

Apex Fintech Solutions Inc. ("Apex"), an innovation launchpad for the global investment ecosystem, has announced the release ...

Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

The PGIM Jennison Focused Growth Fund rose 5.7%, slightly underperforming the Russell 1000 Growth Index. Click here to read ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...